Expanded Access to Neladalkib (NVL-655) for People with Non-Small Cell Lung Cancer

Full Title

Purpose

Researchers are assessing neladalkib for people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has spread beyond its original location. In addition, their cancers have a fusion (genetic change) involving a gene called ALK.

Neladalkib blocks the ALK protein, which is found in cancer cells with the ALK gene. Cancer cells need these proteins to survive and grow. Neladalkib may work well for you because it may keep working after cancer cells stop responding to similar treatments. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have locally advanced or metastatic NSCLC with an ALK gene fusion.
• Have recovered from the serious side effects of prior therapies before taking neladalkib.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Alexander Drilon’s office at 646-608-3758.